AMPH Earnings Prediction
The chart below shows how AMPH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AMPH sees a +2.16% change in stock price 10 days leading up to the earnings, and a +3.40% change 10 days following the report. On the earnings day itself, the stock moves by -0.32%. This data can give you a slight idea of what to expect for the next quarter's release.
AMPH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
191.21M
5.90%
4.84%
Gross Margin
53.31%
-11.21%
2.17%
Operating Margin
29.83%
-25.89%
-1.45%
Net Margin
21.14%
-22.45%
1.59%
EPS
0.78
-14.29%
6.85%
No Data Available
AMPH Earnings Analysis
Amphastar Pharmaceuticals, Inc. Corporation (AMPH.O) Earnings Conference Call
Positive
Net Revenue Increase: In the Q3 of 2024, Amphasstar reported net revenues of $191.2 million marking a 6% increase year-over-year, reflecting the resilience and growing strength of our diversified product portfolio and the strategic initiatives.
BAQSIMI Sales Performance: BAQSIMI sales through Amphasstar totaled $40.4 million in Q3.
Record Quarterly Sales: Sales of Primatene Mist reached $26 million in quarterly sales, achieving its highest quarterly sales since the launch, representing a significant step toward our goal of $100 million in annual sales for this product by the end of 2024.
Cash Flow and Share Repurchase: We had cash flow from operations of approximately $60 million, which allowed us to repurchase 797,000 shares.
Share Buyback Program: We also announced an additional buyback program of $50 million.
Negative
Revenue Increase Amid Challenges: Despite a 6% increase in net revenues to $191.2 million, the company faced challenges with Hurricane Helene impacting logistics and resulting in delayed shipments, which negatively affected expected sales between $2 million and $4 million.
BAQSIMI Sales Decline: Sales of BAQSIMI decreased by approximately $2 million to $3 million due to temporary supply disruptions in 14 European countries, limiting sales opportunities during the quarter.
Glucagon Sales Decline: Glucagon sales declined by 9% to $26.8 million from $29.5 million, attributed to a decrease in units shipped as more patients transitioned to ready-to-use products like BAQSIMI.
Gross Margin Decline: Cost of revenues increased to $89.3 million from $79.2 million, leading to a decline in gross margins to 53% from 60% in the prior year, primarily due to higher costs associated with goods sold.
Net Income Decline: Net income decreased by 18% to $40.4 million, or $0.78 per share, compared to $49.2 million, or $0.91 per share, in the third quarter of 2023.
AMPH FAQs
How does AMPH typically perform around its earnings report dates?
Is Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AMPH Earning Call Sentiment
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AMPH.O
1.73%Positive
The earnings call reveals mixed signals: a slight revenue increase and share repurchase program are positive, but declining net income, gross margin, and competitive pressures are concerning. The Q&A highlights supply disruptions and competitive challenges without offering clear guidance, maintaining a neutral outlook. The market cap suggests moderate volatility, aligning with a neutral prediction.
